Publication: ASEAN Vaccine Manufacturing Research Project: Philippines Country Case Study
Loading...
Date
2023-06-16
ISSN
Published
2023-06-16
Author(s)
Editor(s)
Abstract
The COVID-19 pandemic has had a devastating effect on the ASEAN region, which has recorded over 27 million cases of the virus. Despite rapid development of a range of COVID-19 vaccines using innovative technologies, access to these vaccines has been a challenge, with manufacturing mostly concentrated in the US and Europe for high-value mRNA vaccines, and China and India for traditional platforms and high-volume production. Countries with domestic COVID-19 vaccine manufacturing capacity prioritized domestic vaccine requirements over foreign needs, putting countries with limited production capabilities at a disadvantage. ASEAN countries, which overall have made limited investments in research and development of vaccines and biologicals, were highly dependent on imports, resulting in heightened vulnerability during COVID 19 surges. Despite the existence of an established framework for ASEAN coordination on vaccines, there has been minimal coordination between member states to collectively procure COVID-19 vaccines. Consequently, ASEAN countries have experienced a common set of challenges in navigating the complex global vaccine market to ramp up COVID-19 vaccination. Leaders of ASEAN member states have recognized the need for the region to be self-sufficient in vaccine research and manufacturing to effectively address future pandemics and build regional vaccine security. ASEAN must build regional capacity to develop, test efficacy, and scale up manufacture of vaccines, building on existing country-level strengths and avoiding duplication.
Link to Data Set
Citation
“World Bank. 2023. ASEAN Vaccine Manufacturing Research Project: Philippines Country Case Study. © World Bank. http://hdl.handle.net/10986/40376 License: CC BY-NC 3.0 IGO.”